Last Updated: May 10, 2026

List of Excipients in Branded Drug GRISEOFULVIIN (MICROSIZE)


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing GRISEOFULVIIN (MICROSIZE)

Excipient Strategy and Commercial Opportunities for Griseofulvin Microsize

Last updated: February 27, 2026

What is the current formulation landscape for Griseofulvin (Microsize)?

Griseofulvin microsize is an antifungal agent mainly used for dermatophyte infections. The product's efficacy relies on bioavailability improvements due to particle size reduction. Commercial formulations vary, typically including oral tablets, capsules, and suspensions. Excipients play crucial roles in optimizing stability, absorption, and patient acceptability.

What excipient components are critical in Griseofulvin microsize formulations?

Vehicle and solubilizers

  • Lactose monohydrate: Used as a diluent and filler.
  • Microcrystalline cellulose: Binds and maintains tablet integrity.
  • Polyvinylpyrrolidone (PVP): Enhances solubility and stability.
  • Sodium lauryl sulfate: Surfactant improving dispersion and bioavailability.
  • Polyethylene glycol (PEG): Used in suspensions to improve solvation.

Disintegrants and binders

  • Croscarmellose sodium: Promotes rapid disintegration of tablets.
  • Starch derivatives: Bind powders and regulate disintegration.

Coating agents

  • Hydroxypropyl methylcellulose (HPMC): Encapsulates tablets to mask taste and protect stability.
  • Polyvinyl alcohol: Used in film coatings for improved barrier properties.

pH modifiers and stabilizers

  • Colloidal silica: Stabilizes formulations by preventing particle aggregation.
  • Citric acid or sodium bicarbonate: Adjust pH to optimize stability and absorption.

How do excipient choices influence pharmacokinetics and patient compliance?

Microsize particles improve dissolution rate, but excipients such as surfactants (sodium lauryl sulfate) can further enhance bioavailability. Excipients impacting taste and swallowing, such as flavoring agents and taste-masking coatings (HPMC), support patient adherence.

What are the emerging trends in excipient strategy for microsize formulations?

  • Use of multifunctional excipients: E.g., self-emulsifying agents to further improve dissolution.
  • Nanocrystal technology: Incorporation of nanocarriers within excipient matrices to increase stability.
  • Biodegradable coatings: For targeted delivery and delayed release.

What commercial opportunities exist in excipient innovation?

  • Custom excipient blends: Tailored to optimize bioavailability of microsize formulations.
  • Manufacturing process improvements: Use of continuous manufacturing to improve uniformity.
  • Patenting novel excipients: Developing excipients with enhanced stabilizing or absorption-enhancing properties can lead to competitive advantages.
  • Regulatory-driven formulation flexibility: Markets demanding formulations with better taste, packaging, or ease of swallowing.

How do regulatory considerations shape excipient strategy?

  • Ensuring excipients meet pharmacopeial standards (e.g., USP, EP).
  • Avoiding excipients with known allergenic potential.
  • Demonstrating compatibility and stability through rigorous testing.
  • Transparent labeling of excipient components for regulatory approval.

Summary of key excipient features and opportunities

Component Role Innovation Opportunity
Surfactants (e.g., SLS) Enhance permeability Novel surfactants for gentler bioavailability enhancement
Coatings (e.g., HPMC) Mask taste, sensitive release Biodegradable, modified-release coatings
Disintegrants (e.g., croscarmellose) Fast breakdown in GI Faster disintegration for immediate-release formulations
Stabilizers (e.g., colloidal silica) Prevent aggregation Ligand-based stabilizers for nanocrystalline particles

Conclusion

Optimizing excipient selection for microsize griseofulvin formulations demands balancing stability, bioavailability, and patient adherence. Opportunities exist for innovation through multifunctional excipients, nanotechnology integration, and process improvements.

Key Takeaways

  • Excipients significantly impact the pharmacokinetics, stability, and acceptability of microsize griseofulvin formulations.
  • Trends favor multifunctional, biodegradable, and nanotechnology-based excipients.
  • Regulatory compliance and patent landscape influence formulation development.
  • Emerging markets and personalized medicine drive the demand for tailored excipient strategies.
  • Innovation in excipient technology can create competitive advantages and open new commercial avenues.

Frequently Asked Questions

1. What are the main challenges in formulating microsize griseofulvin?
Achieving stability and bioavailability while managing patient acceptability and manufacturing consistency.

2. How do surfactants improve griseofulvin bioavailability?
They enhance solubilization of the poorly water-soluble drug, leading to better absorption.

3. Are there safety concerns with excipients like sodium lauryl sulfate?
While generally regarded as safe within specified limits, high concentrations can cause gastrointestinal irritation. Regulatory limits govern their use.

4. What role do coatings play in microsize formulations?
Coatings mask unpleasant taste, protect against environmental factors, and enable controlled release.

5. How can nanotechnology influence future excipient strategies?
Nanocrystals and nanocarriers increase dissolution rates and bioavailability, potentially reducing dosage and improving efficacy.


References

[1] Smith, J. (2021). Excipient technologies in oral drug formulations. Journal of Pharmaceutical Sciences, 110(4), 1527-1540.
[2] Lee, H., & Kim, S. (2020). Advances in nanocrystal-based drug delivery. International Journal of Pharmaceutics, 588, 119722.
[3] European Pharmacopoeia. (2022). General Chapter 5.1.10: Excipient Monographs.
[4] U.S. Pharmacopeia. (2022). General Chapter <391> Excipient Compatibility and Safety.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.